EX-21 4 dex21.htm SUBSIDIARIES Subsidiaries

Exhibit 21

Pharmaceutical Product Development, Inc. and Subsidiaries

The subsidiaries of Pharmaceutical Product Development, Inc., as of February 15, 2011, are as follows:

 

     

Name of Subsidiary

   

Jurisdiction of Incorporation
or Organization

1.

    Applied Bioscience International, LLC    Delaware

2.

    PPD Global Central Labs, LLC    Kentucky

3.

    PPD Aeronautics, LLC    North Carolina

4.

    APBI Finance Corporation    Delaware

5.

    PPD GP, LLC    Delaware

6.

    PPD Holdings, LLC    Delaware

7.

    PPD UK Holdings Ltd    United Kingdom

8.

    PPD Development, LP    Texas

9.

    ATP, LLC    North Carolina

10.

    Pharmaco Investments, Inc.    Delaware

11.

    PPD International Holdings, Inc.    Delaware

12.

    PPD France SNC    France

13.

    PPD Scandinavia AB    Sweden

14.

    Pharmaceutical Product Development Spain SL    Spain

15.

    PPD do Brasil-Suporte a Pesquisa Clinica Ltda.    Brazil

16.

    PPD Argentina, S.A.    Argentina

17.

    PPD International Holdings, Inc. y Compania Limitada    Chile

18.

    Pharmaceutical Product Development South Africa (Pty) Ltd    South Africa

19.

    PPD Canada, Ltd.    Canada

20.

    PPD Australia Pty Ltd    Australia

21.

    PPD International Holdings GmbH    Germany

22.

    PPD Germany GmbH    Germany

23.

    PPD Poland Sp. Z o.o.    Poland

24.

    PPD Czech Republic s.r.o.    Czech Republic

25.

    PPD Germany GmbH & Co KG    Germany

26.

    PPD Hungary Research & Development Limited    Hungary

27.

    PPD Italy S.r.l.    Italy

28.

    PPD Mexico, S.A. de C.V.    Mexico

29.

    PPD Development (Thailand) Co., Ltd    Thailand

30.

    PPD Japan K.K.    Japan

31.

    PPD Global, Ltd    United Kingdom

32.

    Clinical Technology Centre (International) Ltd    United Kingdom

33.

    Cambridge Applied Nutrition Toxicology & Biosciences Ltd    United Kingdom

34.

    Clinical Science Research International Ltd    United Kingdom

35.

    Leicester Clinical Research Centre Ltd    United Kingdom

36.

    Chelmsford Clinical Trials Unit Ltd    United Kingdom

37.

    Gabbay Ltd    United Kingdom

38.

    Data Analysis & Research (DAR) Ltd    Scotland

39.

    PPD Global Central Labs BVBA    Belgium

40.

    PPD Development (S) Pte Limited    Singapore

41.

    PPD Development (HK) Limited    Hong Kong

42.

    PPD (Netherlands) BV    Netherlands

43.

    PPD Pharmaceutical Development India Private Limited    India

 

1

44.

    River Ventures, LLC    North Carolina

45.

    PPD Slovak Republic s.r.o.    Slovak Republic

46.

    PPD Peru S.A.C.    Peru

47.

    PPD Vaccines and Biologics, LLC    Pennsylvania

48.

    PPD Pharmaceutical Development (Beijing) Co., Ltd    China

49.

    Greenbird Limited    Cyprus

50.

    PPD Development Ireland Ltd    Ireland

51.

    Limited Liability Company PPD Development (Smolensk)    Russia

52.

    PPD Global Central Labs (S) Pte. Ltd.    Singapore

53.

    Limited Liability Company Contract Research Organization Innopharm – Ukraine    Ukraine

54.

    PPD Dermatology, LLC    Delaware

55.

    AbC.R.O., Inc.    Virginia

56.

    PPD BULGARIA EOOD    Bulgaria

57.

    BioDuro LLC    Delaware

58.

    BioDuro (Mauritius)    Mauritius

59.

    BIODURO (BAONUO) BEIJING TECHNOLOGY CO., LTD.    Beijing, China

60.

    Excel Pharmastudies, Inc.    Cayman

61.

    Excel Pharmastudies Inc.    Beijing, China

62.

    EXCEL PHARMASTUDIES TAIZHOU BIOMETRICS, INC.    China

63.

    EXCEL PHARMASTUDIES TAIZHOU VACCINE, INC.    China

64.

    Excel Pharmastudies (US), Inc.    California

65.

    PPD CT Investments LLP    United Kingdom

66.

    PPD Romania SRL    Romania

67.

    AbC.R.O. d.o.o.    Croatia

68.

    AbC.R.O. Poland Sp. Z o.o.    Poland

69.

    Limited Liability Company ABC.R.O. (ooo ABC.R.O.)    Russia

70.

    X-Chem, Inc.    Delaware

71.

    PPD Colombia S.A.S.    Colombia

72.

    PPD (Guatemala), S.A.    Guatemala

73.

    BioDuro Biologics Pte. Ltd.    Singapore

 

2

Subsidiaries 1, 2, 47 and 54 are wholly-owned subsidiaries of Pharmaceutical Product Development, Inc.

Subsidiaries 5 and 6 are wholly-owned subsidiaries of Subsidiary 1.

Subsidiary 8 is owned 99.9% by Subsidiary 6 and 0.1% by Subsidiary 5.

Subsidiaries 3, 4, 9, 10, 11, and 44 are wholly-owned subsidiaries of Subsidiary 8.

Subsidiaries 13, 18, 19, 20, 21, 27, 30 and 55 are wholly-owned subsidiaries of Subsidiary 11.

Subsidiary 12 is owned 99.999% by Subsidiary 11 and 0.01% by Subsidiary 1.

Subsidiary 14 is owned 99.231 % by Subsidiary 11 and 0.769% by Subsidiary 8.

Subsidiary 15 is owned 99.99% by Subsidiary 11 and 0.01% by Pharmaceutical Product Development, Inc.

Subsidiary 16 is owned 95% by Subsidiary 11 and 5% by Subsidiary 1.

Subsidiary 17 is owned 99% by Subsidiary 11 and 1% by Subsidiary 1.

Subsidiaries 22 and 23 are wholly-owned subsidiaries of Subsidiary 21.

Subsidiary 24 is owned 97.78% by Subsidiary 21 and 2.22% by Subsidiary 11.

Subsidiary 25 is a wholly- owned subsidiary of Subsidiary 21.

Subsidiary 26 is owned 96.67% by Subsidiary 21 and 3.33% by Subsidiary 11.

Subsidiary 28 is owned 99.99% by Subsidiary 11 and 0.01% by Subsidiary 8.

Subsidiary 29 is owned 99.99% by Subsidiary 11 and 1 share is held by each of Subsidiary 7 and Subsidiary 40.

Subsidiaries 31, 35, 36, 37, 38, 40, 42, 50, 52, 56, 57 and 60 are wholly-owned subsidiaries of Subsidiary 7.

Subsidiary 32 is owned 99% by Subsidiary 31 and 1% by Subsidiary 7.

Subsidiary 33 is owned 50% by Subsidiary 7 and 50% by Subsidiary 31.

Subsidiary 34 is a wholly-owned subsidiary of Subsidiary 31.

Subsidiary 39 is 99.9% owned by Subsidiary 7 and 0.1% by Subsidiary 31.

Subsidiary 41 is 50% owned by Subsidiary 40 and 50% by Subsidiary 1.

Subsidiary 43 is owned 99.99% by Subsidiary 7 and .01% by Subsidiary 31.

Subsidiary 45 is owned 85% by Subsidiary 7 and 15% by Subsidiary 31.

Subsidiary 46 is owned 99.99% by Subsidiary 11 and .01% by Subsidiary 1.

Subsidiary 48 is a wholly-owned subsidiary of Subsidiary 40.

Subsidiary 49 is owned 99.95% by Subsidiary 7 and 0.05% by Subsidiary 42.

Subsidiary 51 is a wholly-owned subsidiary of Subsidiary 49.

Subsidiary 53 is a wholly-owned subsidiary of Subsidiary 51.

Subsidiary 7 is 99.6% owned by Subsidiary 11 and 0.4% by Subsidiary 55.

Subsidiary 58 is a wholly-owned subsidiary of Subsidiary 57.

Subsidiary 59 is a wholly-owned subsidiary of Subsidiary 58.

Subsidiary 61 and 64 are wholly-owned subsidiaries of Subsidiary 60.

Subsidiary 62 is 50% owned by Subsidiary 61 and 50% by an unrelated third party.

Subsidiary 63 is 33.33% owned by Subsidiary 61, 16.67% by Subsidiary 62 and 50% by an unrelated third party.

Subsidiary 65 is 80% owned by Subsidiary 4 and 20% by Subsidiary 11.

Subsidiary 66 is 99.3% owned by Subsidiary 55 and 0.7% by Subsidiary 56.

Subsidiaries 67 and 68 are wholly-owned subsidiaries of Subsidiary 55.

Subsidiary 69 is 75% owned by Subsidiary 56 and 25% by Subsidiary 55.

Subsidiary 70 is owned 60% by Pharmaceutical Product Development, Inc. and 40% owned by an unrelated third party.

Subsidiary 71 is a wholly-owned subsidiary of Subsidiary 7.

Subsidiary 72 is 99% owned by Subsidiary 11 and 1% by Subsidiary 1.

Subsidiary 73 is 75% owned by Subsidiary 40 and 25% by an unrelated third party.

 

3